Abstract: Systems and methods of implementing a secured cloud environment allow for design and instantiation of a security policy at the infrastructure level. An example system may comprise a first module to facilitate selecting at least two cloud computing component templates from a cloud computing component catalog. The system may comprise a second module to facilitate defining a connection between the at least two selected cloud computing component templates. The system may comprise a third module to facilitate assigning a security level and a policy to at least one of the at least two selected cloud computing component templates. The system may comprise a fourth module to facilitate building a cloud computing component blueprint.

Abstract: Provided is a system, method, and computer-readable storage medium having one or more computer-readable instructions thereon for providing leased images in cloud computing environments. The method includes monitoring a usage of a leased image provided by a cloud vendor, by a client computing device. A threshold period of time associated with the usage is determined. Whether an access to the leased image should be terminated based upon an expiry of the threshold period of time or based upon a request received from the client computing device is determined. The image is locked based upon whether the access to the leased image should be terminated. An access request received for the locked image is monitored; and access to the locked image is enabled when it is determined that the access request is valid.

Abstract: Provided herein are systems and methods for providing isolated virtual image communication in a virtual computing environment. Initially, a guest virtual machine that is activated in a virtual computing environment may be isolated into a private network. A service request may then be formulated at the guest virtual machine and addressed to a predetermined non-existent address. The request is then ostensibly sent to the predetermined address, whereupon the service request is actually transmitted to a shared resource with a security appliance machine in the virtual computing environment. The request is then forwarded to the security appliance machine and a reply formulated. The reply is sent back to the guest virtual machine via the shared resource.

Abstract: Provided herein are systems and method enabling secure virtual image access in a virtual or cloud computing environment. The systems and methods include assigning a status to indicator to guest virtual machines (virtual images) that provide applications and other services to cloud consumers in the cloud environment. A virtual appliance machine in the cloud environment maintains the status of the guest virtual machines and makes decisions based on the status as to whether to allow access to the guest virtual machines. These decisions are transmitted to local elements on the guest virtual machines, which enforce access control on a local level. In this manner, unauthorized virtual image access is prevented providing increased security and data integrity.

Abstract: A system and method for controlling access to virtual machine consoles. The system includes a console access controller configured to register an owner to a virtual machine to open a defined limit of consoles and capture the defined limit of consoles. An image console control is configured to receive a request to check-out one or more of the captured consoles in one of an exclusive mode and a shared mode and determine whether the check-out request was made by the owner. The console access controller is further configured to open the one or more captured consoles in the exclusive mode to the owner if the check-out request is made by the owner and recapturing the one ore more consoles in response to a check-in request from the owner.

Abstract: A device for drug delivery to an orifice of a subject, comprising a shell which is elastically stressed by an active pharmaceutical ingredient, said shell containing and being substantially impermeable to said active pharmaceutical ingredient, wherein said shell has at least one hole sized for in-vivo release of said active pharmaceutical ingredient as a result of elastic stressing.

Abstract: A reduction in the side effects of treating with an agent having combined 5HT2/5HT3 and alpha-2 antagonistic activity is obtained by administering an agent having histamine H1 receptor agonist activity. A combined dosage form comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and an agent having histamine H1 receptor agonist activity is presented. Some embodiments of the combined dosage form comprise an immediate release component comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and a delayed release component comprising an agent having histamine H1 receptor agonist activity. Some embodiments of the combined dosage form comprise a delayed release component comprising an agent having 5HT2/5HT3 and alpha-2 antagonistic activity and an immediate release component comprising an agent having histamine H1 receptor agonist activity. Methods of treatment and kits for administration are also provided.

Abstract: Methods and compositions for preventing or reducing weight gain associated with drug treatment, which utilize an H1 agonist such as betahistine, betahistine metabolite or a betahistine salt are disclosed.

Abstract: A method of reducing weight gain associated with olanzapine treatment in a human subject, by orally administering to an olanzapine-treated subject betahistine or a salt thereof, is disclosed.

Abstract: Pharmaceutical compositions are disclosed comprising betahistine, or a salt thereof, and olanzapine in amounts effective to reduce the weight gain associated with olanzapine administration.

Abstract: A rectally insertable device for localized drug delivery to the anal sphincter of a subject, a method of using the device and the use of the device is disclosed. The device comprises a shell for containing an active pharmaceutical ingredient, the shell being substantially impermeable to the active pharmaceutical ingredient wherein a lower portion of the shell is configured to release the active pharmaceutical ingredient from the shell and wherein when the device is inserted into the rectum of the subject, the lower portion of the shell is proximal to the anal sphincter, such that the active pharmaceutical ingredient is released proximal to the anal sphincter.

Abstract: Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows am efficient treatment regime thereof are disclosed. The methods and compositions can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia and for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject.

Abstract: Methods for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia.

Abstract: Methods for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed.

Abstract: Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods and compositions can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia and for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject.

Abstract: Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods and compositions can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia and for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject.

Abstract: Methods for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia.

Abstract: Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods and compositions can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia and for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject.

Abstract: Methods for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia.

Abstract: Methods for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed.